Abstract
Long-term follow-up on Total Therapy I revealed, with a median follow-up of about 10 years, median durations of event-free survival (EFS) and overall survival (OS) of 37 and 80 mos in the 88% of patients lacking cytogenetic abnormalities (CA) of chromosome 13 compared to only 28 and 34 mos in those with CA 13. Total Therapy II (TT II) was developed to test whether more intensive remission induction and post-tandem transplant consolidation chemotherapy prior to interferon maintenance could further improve clinical outcome. All patients were also randomized to ± thalidomide at a starting dose of 400 mg. Results obtained in the first 231 patients enrolled in TT II are presented for the two study arms combined (data for effect of thalidomide still blinded). Three-year projection of EFS and OS are 71% and 77%. On an intent-to-treat basis, 66% achieved complete remission (CR) or near-CR. Major independent adverse features associated with shortened survival included CA and chromosome 13 deletion using interphase FISH. CA identified 29 among 102 patients with FISH 13 deletion who had a very grave prognosis (3 yr EFS, 32%; OS 49%) compared to all remaining patients who enjoyed 3 yr EFS of 79% and OS of 83%. Thus, both cytogenetics and FISH are recommended in the initial evaluation of patients with MM.
Similar content being viewed by others
References
Barlogie B, Jagannath S, Desikan R, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma.Blood. 1999;93:55–65.
Barlogie B, McCoy J, Shaughnessy J, et al. Total therapy II (TTII) for newly diagnosed multiple myeloma (MM); preliminary data on feasibility and efficacy in the first 231 enrolled patients; comparison with predecessor trial total therapy I (TTI) (N=231).Blood. 2001;98:2857a.
Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma.New England Journal of Medicine. 1999;341:1565–1571.
Barlogie B, Spencer T, Tricot G, et al. Long term follow up of 169 patients receiving a Phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM).Blood. 2000;96:2213a.
Drach J, Schuster J, Nowony H, et al. Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization.Cancer Research. 1995;55:3854–3859.
Facon T, Avet-Loiseau H, Guilerm G, et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta-2-microglobulin produce a powerful myeloma staging system for patients receiving high dose therapy.Blood. 2001;97:1566–1571.
Shaughnessy J, Barlogie B, et al. Prognostic impact of cytogenetic and interphase FISH defined chromosome 13 deletion in multiple myeloma: early results of total therapy II.Br J Hematol. (in press).
Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-Versus-Myeloma Effect: Proof of Principle.Blood. 1996;87:1196–1198.
Badros A, Barlogie B, Morris C, et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions.Blood. 2001;97:2574–2579.
Zhan F, Hardin J, Bumm K, et al. Molecular profiling of multiple myeloma.Blood. in press.
Author information
Authors and Affiliations
About this article
Cite this article
Barlogie, B., Shaughnessy, J.D. Early results of total therapy II in multiple myeloma: Implications of cytogenetics and FISH. Int J Hematol 76 (Suppl 1), 337–339 (2002). https://doi.org/10.1007/BF03165280
Issue Date:
DOI: https://doi.org/10.1007/BF03165280